Abstract:
This is a prospective and longitudinal cohort study carried out in Khartoum State in Radio Isotop Center Khartoum , Omdurman Millitary Hospital and GafarIbnAufPaediatric Hospital in the period from (May 2015 to May 2017) to detect KITD 816 mutation and its association with outcome of Sudanese Acute Myeloid Leukaemia patients at Khartoum state under same chemotherapy treatment plan .Thirty diagnosed AML patients with different subtypes of AML FAB classifications (M0,M1,M2,M4,M5,M6) were selected 14 (46%) male and 16(53%) female.The age was range from(5-70 years) ,4.5 ml of venous blood was withdrawn from each patients placed in 1%EDTA container it was divided for two parts, 200ul of blood for DNA extraction and the other part for CBC analysis, which would be replicated to all patients monthly with monitoring the clinical findings to follow up of patient's outcome during this period (minimum period to follow up 5 months ).The results was analyzed by SPSS version 19.They AML patients were enrolled for two study groups:23(76.6%) patients were KIT D 816 mutation positive as case group and the other group contain 7(23.3%) patients were KIT D 816 mutation negative act as control group .The results showed association of KIT D 816 mutation with AML disease (p.value=0.00),adverse patient's outcome if corresponded with some AML subtypes(M0,M4 and M5) (p.value=0.05) and males were high frequent than female (p.value=0.008) but no association between KIT D 816 mutation with patient's outcome generally and age of AML patients (p.value=0.666).
In light of this study resultsKIT D 816 mutation should be considered as diagnosed cytogenetic test of AML disease and to determine suitable treatment plan to benefit outcome.
